The World Health Organization (WHO) has announced recommendations for the composition of influenza vaccines for the 2026-2027 northern hemisphere influenza season, a crucial step in preparing for the annual respiratory virus threat. Seasonal influenza, a highly contagious acute respiratory infection, is estimated to cause up to 650,000 respiratory deaths globally each year, underscoring the importance of proactive public health measures and timely vaccine updates. The updated vaccine aims to provide the best possible protection against circulating strains and reduce the burden of severe illness, and mortality.
The recommendations follow a four-day consultation involving experts from the WHO’s Global Influenza Surveillance and Response System (GISRS), a longstanding global platform dedicated to tracking influenza activity and viral evolution. This system plays a vital role in monitoring changes in influenza viruses throughout the year, enabling clinicians and vaccine developers to adjust vaccine formulations in advance of each influenza season. The ongoing surveillance is essential for ensuring vaccine effectiveness.
This year’s update was largely driven by the global spread of a new A(H3N2) variant, classified as J.2.4.1, similarly referred to as “subclade K,” which emerged in August 2025. The rapid expansion of this variant contributed to early and unusually intense influenza activity in several countries, prompting the need for a revised vaccine composition. According to the WHO, influenza A viruses have been dominant with relatively few detections of influenza B, and no confirmed cases of B/Yamagata since early 2020.
Updated Vaccine Strains for 2026-2027
For the upcoming influenza season, the WHO recommends specific strains for both egg-based and cell- or recombinant-based vaccine platforms. Egg-based vaccines should include an A/Missouri/11/2025 (H1N1)pdm09-like virus, an A/Darwin/1454/2025 (H3N2)-like virus, and a B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus. Cell culture-, recombinant protein- or nucleic acid-based vaccines should include an A/Missouri/11/2025 (H1N1)pdm09-like virus, an A/Darwin/1415/2025 (H3N2)-like virus, and a B/Pennsylvania/14/2025 (B/Victoria lineage)-like virus. These strains were selected based on their close match to the viruses currently circulating globally.
Zoonotic Influenza Remains a Concern
Beyond seasonal influenza, experts are also closely monitoring zoonotic influenza viruses, which originate in animals and pose a potential pandemic threat. Since September 2025, 25 human cases linked to zoonotic influenza have been reported across six countries, with infections primarily resulting from exposure to infected animals or contaminated environments. Importantly, no human-to-human transmission has been identified to date. In anticipation of potential future threats, the WHO panel advised developing a new candidate vaccine virus targeting A(H9N2).
The WHO’s recommendations are used by national vaccine regulatory agencies and pharmaceutical companies worldwide to develop, produce, and license influenza vaccines for the upcoming season. This collaborative effort aims to ensure that vaccines are closely matched to the viruses expected to circulate, offering the best possible protection against severe illness and death. The process highlights the interconnectedness of global health security.
For healthcare professionals, the updated vaccine composition reinforces the critical importance of vaccination, particularly among high-risk groups. Annual vaccination remains the most effective way to prevent severe influenza and its complications. The annual update ensures vaccines offer the closest possible protection against current and emerging strains, supporting global efforts to reduce hospitalizations, severe disease, and mortality.
Disclaimer: This article provides informational content about influenza and vaccine recommendations and should not be considered medical advice. Please consult with a qualified healthcare professional for personalized guidance on influenza prevention and treatment.
The ongoing surveillance and adaptation of influenza vaccines demonstrate a commitment to protecting public health against a constantly evolving virus. Continued monitoring of circulating strains and emerging zoonotic threats will be essential in the coming months. What remains to be seen is the effectiveness of the updated vaccine composition in real-world conditions as the 2026-2027 influenza season unfolds.
What are your thoughts on the updated influenza vaccine recommendations? Share your comments below, and please share this article with your network to support spread awareness about influenza prevention.
